IMO Health is excited to announce the appointment of Matt McKinley as its first General Manager of Life Sciences. This new leadership role underscores the company’s commitment to advancing data quality and evidence generation across the entire healthcare ecosystem.
“Real-world data is now indispensable for drug development, payer negotiations, and regulatory submissions, but without clinically precise terminology and normalization, that data is fragmented and often unreliable,” said Ann Barnes, CEO of IMO Health. “By investing in life sciences, we’re extending our proven leadership in provider data quality to help pharma, biotech, and clinical research organizations unlock the full potential of their evidence resources.”
As part of this expansion, IMO Health has hired Matt McKinley to spearhead strategy and execution of the Life Sciences business. He brings more than 20 years of leadership experience in healthcare data solutions, spanning pharma, medical devices, diagnostics, and clinical trials and will play a pivotal role in building solutions that align the needs of life sciences with the realities of clinical care.
“The importance of real-world data in life sciences has never been greater – but its true value can only be unlocked when the clinical intent behind each data point is preserved,” said McKinley. “Through its deep clinical understanding and data enrichment framework, IMO Health bridges the gap between how care is documented and how it’s used to drive discovery and better outcomes. This is just the beginning of what we can enable for evidence generation, clinical trials, and beyond.”
As RWD becomes increasingly central to therapy development and clinical trial design, the industry continues to grapple with messy, inconsistent data and billing codes that were never built to capture clinical nuance. By embedding provider-native terminology, scalable normalization, and GenAI-powered technology, IMO Health ensures that life sciences organizations can derive trustworthy, reproducible insights from the data they invest in, accelerating evidence generation, improving trial efficiency, and advancing patient care.
With this expanded focus, IMO Health signals a new era of partnership with companies in pharma, biotech, and CROs, extending its legacy of data quality leadership from the provider space into the broader life sciences ecosystem.
